IP Library Granted Patent US 10,179,106
Granted Patent B2
US 10,179,106 · App. 14/115,869 · Granted Jan 15, 2019

Liposomes comprising polymer-conjugated lipids and related uses

Inventor: Saul Yedgar (Jerusalem, IL)
Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
A61K9/127A61K9/1271A61K31/713A61K47/48815
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,106
App. No.
14/115,869
Granted
Jan 15, 2019
Kind
B2
Abstract

The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.

Claims (19)

1. A liposome comprising a lipid bilayer and a polymer-conjugated phospholipid, wherein said polymer-conjugated phospholipid is incorporated into said lipid bilayer, and wherein said polymer is a polysaccharide.

2. The liposome of claim 1 , wherein said liposome is a nanoliposome.

3. The liposome of claim 1 , wherein said polymer-conjugated lipid comprises two or more lipids conjugated to a single polymer.

4. The liposome of claim 1 , wherein the ratio of phospholipids to polymer units in said polymer-conjugated phospholipid is between 2:4 and 2:2000.

5. The liposome of claim 1 , wherein said polysaccharide is selected from the group consisting of glycosaminoglycan, chitosan, alginic acid, hetastarch and dextran.

6. The liposome of claim 5 , wherein said glycosaminoglycan is selected from the group consisting of hyaluronic acid, chondroitin, keratan, dermatan, and heparin.

7. The liposome of claim 5 , wherein said glycosaminoglycan has an average molecular weight of 5-90 kD.

8. The liposome of claim 1 , wherein said polymer is conjugated to said phospholipid via a glutaryl linker.

9. The liposome of claim 1 , wherein said phospholipid is phosphatidylethanolamine.

10. The liposome of claim 1 , wherein said liposome further comprises a polyethylene glycol (PEG)-conjugated lipid.

11. A method of producing a mixed liposome of claim 1 , comprising the step of conjugating a phospholipid with a polymer to form a polymer-conjugated phospholipid and contacting said polymer-conjugated phospholipid with a liposome to produce a mixed liposome.

12. The method of claim 11 , further comprising the step of isolating said polymer-conjugated lipid prior to said contacting step.

13. A method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a liposome of claim 1 to said subject.

14. A method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a liposome of claim 1 to said subject and imaging said patient.

15. A method for treating, inhibiting or suppressing a pathological condition in a subject, comprising administering to said subject a liposome of claim 1 .

16. The method of claim 15 , wherein said pathological condition is selected from the group consisting of cancer, infection, obstructive respiratory disease, dermatological condition, cystic fibrosis, eye disorder, inflammatory bowel disease, and nervous system disorder.

17. The method of claim 15 , wherein said liposome further comprises a bioactive agent for treating said pathological condition.

18. The method of claim 15 , wherein said drug is administered orally, intravenously, intranasally, intraocularly, intramuscularly, subcutaneously or topically.

19. The method of claim 1 , wherein a packing parameter relating to the ratio of lipid to polymer-conjugate has a value of 1.0.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2013
From: YEDGAR, SAUL
To: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
Reel/Frame 031550/0027 →
Continuity (2)
Provisional Application 61485192 · May 12, 2011
Related Publication 20140199241A1 · Jul 17, 2014
Cited By (1)
US 12,351,803